AI Quick Summary

🔍 Meet the residents across our SI Parks ! 🔎@CNS Therapy, a company based in the @Switzerland Innovation Park Basel Area - Site Jura, has a clear mission: to develop a non-invasive, low-risk therapy for chronic pain patients. While many conventional treatments for chronic pain rely on drugs and implants, CNS Therapy makes chronic pain patients #pain-free by combining a new physiological approach - Systolic Extinction Therapy (SET), a patented medical device - and interactive therapy.As a winner of @DayOne Tech Accelerator 2022, a 12-month program for medical technology companies, CNS Therapy has just received seed round funding of CHF 1,000,000 from private investors and CHF 139,200 from the Canton of #Jura.💬 What will the funds be used for? To finalize their patented innovative medical device and the regulatory filing to the #FDA under the 510K program. Learn more about their work in our interview with Co-Founder @Marc Mathys.#SwitzerlandInnovation #whyswitzerland #medtech #Innovation #healthcare@basel area Business & Innovation

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 7/29/2024 9:33:08 AM
• Modified Date: 9/24/2024 12:33:31 PM

Post Description

🔍 Meet the residents across our SI Parks ! 🔎

@CNS Therapy, a company based in the @Switzerland Innovation Park Basel Area - Site Jura, has a clear mission: to develop a non-invasive, low-risk therapy for chronic pain patients. While many conventional treatments for chronic pain rely on drugs and implants, CNS Therapy makes chronic pain patients #pain-free by combining a new physiological approach - Systolic Extinction Therapy (SET), a patented medical device - and interactive therapy.

As a winner of @DayOne Tech Accelerator 2022, a 12-month program for medical technology companies, CNS Therapy has just received seed round funding of CHF 1,000,000 from private investors and CHF 139,200 from the Canton of #Jura.

💬 What will the funds be used for? To finalize their patented innovative medical device and the regulatory filing to the #FDA under the 510K program.

Learn more about their work in our interview with Co-Founder @Marc Mathys.

#SwitzerlandInnovation #whyswitzerland #medtech #Innovation #healthcare

@basel area Business & Innovation